HC Wainwright Issues Optimistic Estimate for TPST Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Investment analysts at HC Wainwright raised their FY2025 earnings per share estimates for shares of Tempest Therapeutics in a research note issued on Thursday, January 22nd. HC Wainwright analyst J. Pantginis now expects that the company will earn ($6.10) per share for the year, up from their prior estimate of ($12.78). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2025 earnings at ($0.62) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($2.28) EPS and FY2028 earnings at ($2.13) EPS.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($3.27) by $2.48.

TPST has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a report on Monday, December 29th. Wall Street Zen raised shares of Tempest Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 11th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Tempest Therapeutics presently has an average rating of “Reduce” and an average target price of $12.50.

Tempest Therapeutics Trading Down 2.9%

Tempest Therapeutics stock opened at $2.98 on Monday. The company has a market capitalization of $14.69 million, a PE ratio of -0.30 and a beta of -2.43. Tempest Therapeutics has a 12 month low of $2.40 and a 12 month high of $13.13. The stock has a 50-day moving average price of $3.31 and a two-hundred day moving average price of $7.25.

Shares of Tempest Therapeutics are set to split before the market opens on Friday, January 30th. The 2-1 split was recently announced. The newly issued shares will be distributed to shareholders after the closing bell on Thursday, January 29th.

Institutional Trading of Tempest Therapeutics

A hedge fund recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. grew its holdings in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,560 shares of the company’s stock after purchasing an additional 27,952 shares during the quarter. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 22.52% of the stock is owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.